BAY 573035Alternative Names: BAY 57-3035
Latest Information Update: 09 Jul 2002
At a glance
- Originator Bayer
- Mechanism of Action Adenosine deaminase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Angina pectoris
Most Recent Events
- 19 Sep 2000 Preclinical development for Angina pectoris in Germany (Unknown route)